Proceedings of the National Academy of Sciences · 2013 · 265 citations · 20 references
MedicineMolecular BiologyOncologyChemotherapyDna RepairMolecular OncologyCancer Cell SignalingDna Damage SignalingDna Repair In CarcinogenesisTherapeutic ResistanceBrca MutationsHomologous Recombination RepairParp InhibitionParp Inhibitor ResistancePoly Adp-ribose Polymerase InhibitorsRad51 Filament FormationRad51 ProteinRad51 Regulation
Breast Cancer Type 1 Susceptibility Protein (BRCA1)-deficient cells have compromised DNA repair and are sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. Despite initial responses, the development of resistance limits clinical efficacy. Mutations in the BRCA C-terminal (BRCT) domain of BRCA1 frequently create protein products unable to fold that are subject to protease-mediated degradation. Here, we show HSP90-mediated stabilization of a BRCT domain mutant BRCA1 protein under PARP inhibitor selection pressure. The stabilized mutant BRCA1 protein interacted with PALB2-BRCA2-RAD51, was essential for RAD51 focus formation, and conferred PARP inhibitor as well as cisplatin resistance. Treatment of resistant cells with the HSP90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin reduced mutant BRCA1 protein levels and restored their sensitivity to PARP inhibition. Resistant cells also acquired a TP53BP1 mutation that facilitated DNA end resection in the absence of a BRCA1 protein capable of binding CtIP. Finally, concomitant increased mutant BRCA1 and decreased 53BP1 protein expression occur in clinical samples of BRCA1-mutated recurrent ovarian carcinomas that have developed resistance to platinum. These results provide evidence for a two-event mechanism by which BRCA1-mutant tumors acquire anticancer therapy resistance.
20
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer, Nuala McCabe, Christopher J. Lord et al. · Nature · 2005 · 6.7K citations
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers
Peter C.C. Fong, David S. Boss, Timothy A. Yap et al. · New England Journal of Medicine · 2009 · 3.6K citations · Full text
Medicine, Oncology, Pharmacology +17
Mutational Processes Molding the Genomes of 21 Breast Cancers
Serena Nik‐Zainal, Ludmil B. Alexandrov, David C. Wedge et al. · Cell · 2012 · 2K citations · Full text
Life Sciences, Genetics, Oncology +14
Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells
Ralph Scully, Junjie Chen, Annemieke W. Plug et al. · Cell · 1997 · 1.5K citations · Full text
Human CtIP promotes DNA end resection
Alessandro A. Sartori, Claudia Lukas, Julia Coates et al. · Nature · 2007 · 1.3K citations · Full text